Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Head and Neck Neoplasms 4 Esophageal Neoplasms 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Ovarian Neoplasms 2 Neoplasms 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Urologic Neoplasms 1 Triple Negative Breast Neoplasms 1 Thoracic Diseases 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Rectal Neoplasms 1 Prolactinoma 1 Pituitary ACTH Hypersecretion 1 Peritoneal Diseases 1 Paraproteinemias 1 Pancreatic Ductal Adenocarcinoma 1 Ovarian Diseases 1 Neuroblastoma 1 Nervous System Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Monoclonal Gammopathy of Undetermined Significance 1 Mesothelioma, Malignant 1 Lymphoma 1

Interventions

Cyclophosphamide 101 Etoposide 60 Carboplatin 55 Vincristine 51 Filgrastim 49 Topotecan 44 Temozolomide 44 Melphalan 44 Isotretinoin 44 Doxorubicin 44 Irinotecan 42 Cisplatin 35 3-Iodobenzylguanidine 34 Peripheral Blood Stem Cell Transplantation 31 dinutuximab 30 Granulocyte Colony-Stimulating Factor 30 Radiotherapy 29 sargramostim 28 Granulocyte-Macrophage Colony-Stimulating Factor 25 Busulfan 22 Magnetic Resonance Spectroscopy 19 aldesleukin 18 Thiotepa 18 fludarabine 17 Interleukin-2 17 humanized 3F8 anti-GD2 monoclonal antibody 16 etoposide phosphate 16 naxitamab 15 Ifosfamide 15 Biopsy 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroblastoma × Tissue Banks × Clear all

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Dana-Farber Cancer Institute

Phase 1 Terminated

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡